Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Autor: Garber, Aj, King, Ab, Del Prato, S, Sreenan, S, Balci, Mk, Muñoz Torres, M, Rosenstock, J, Endahl, La, Francisco, Am, Hollander, P, Protich, M, Ivanov, V, Veleva, N, Pichmanova, M, Guerenova, J, Hristozov, K, Slavcheva, A, Petrova, Gancheva, Prakova Teneva, Z, Böhmer, M, Clever, Hu, Kaiser, M, Peter Kempe, H, Mölle, A, Paulus, R, Rose, L, Sauter, J, Kinsley, B, Nolan, J, Hayes, F, Joshi, P, Khutsoane, Dt, Reddy, J, Mayet, L, Burgess, Lj, Raya, Pm, Cros, Mr, Calle, A, Candil, Sd, Soto, A, Francisco, J, Torres, M, Dominguez, Jr, Mesa, J, Mur, Al, Filetti, S, Piatti, P, Vespasiani, G, Santeusanio, F, Fanelli, Carmine Giuseppe, Mannucci, E, Consoli, A, Pata, P, Cignarelli, M, Borzì, V, Trevisan, R, Serban, V, Catrinoiu, D, Creteanu, G, Pop, L, Coman, A, Dogadin, S, Dvoryashina, I, Karpova, I, Lysenko, T, Smirnova, E, Yakusevich, V, Fábry, J, Ilavská, A, Tomášová, L, Tošerová, E, Chow, Fc, Karsidag, K, Erguney, M, Akbay, E, Balçi, Mk, Anderson, C, Baker, C, Berbano, R, Blevins, T, Broadstone, V, Brody, M, Brunner, J, Brusco, O, Case, C, Cherlin, R, Chuck, L, Clower, J, Connor, G, Cooperman, M, Paysinger, A, Early, M, Elliott, S, Fitz Patrick, D, Furlong, K, Garber, A, Glaser, L, Albert, S, Griffing, G, Handke, L, Harris, R, Hermayer, K, Huntley, R, Kaye, W, Kennedy, J, King, A, Klein, E, Lipetz, R, Snell, P, Morawski, E, Nurnberg, R, Orr, R, Osei, K, Palace, E, Raad, G, Rasmussen, B, Reeves, M, Roberts, V, Rodbard, H, Rosenblit, P, Selam, Jl, Shaw, S, Shelmet, J, Simon, H, Smith, M, Stringam, S, Sussman, A, Testa, J, Mazza, A, Varano, S, Warren, M, Winkle, P, Wise, J, Aroda, V, Strzinek, R, Wong, M, Pollock, J, Bode, B.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3982::2ad6aa94253a2f2a8b3e1642b79e9116
http://hdl.handle.net/11391/912344

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.

Autor: Rodbard HW; Endocrine and Metabolic Consultants, Rockville, MD, USA., Cariou B; Department of Endocrinology, l'Institut du Thorax, Nantes University Hospital, Nantes, France., Pieber TR; Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria., Endahl LA; Novo Nordisk A/S, Søborg, Denmark., Zacho J; Novo Nordisk A/S, Søborg, Denmark., Cooper JG; Department of Medicine, Stavanger University Hospital, Stavanger, Norway.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2016 Mar; Vol. 18 (3), pp. 274-80. Date of Electronic Publication: 2016 Jan 11.

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Autor: Zinman B; Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, ON, Canada. zinman@lunenfeld.ca, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C

Publikováno v: Lancet (London, England) [Lancet] 2011 Mar 12; Vol. 377 (9769), pp. 924-31.